The mechanism of action of Platinib (Pujihua) and its advantages in the treatment of RET fusion mutations

Pralsetinib is a new type of targeted drug that is a selective RET inhibitor. RETGene fusion or mutation is one of the driving factors for a variety of malignant tumors, especially common in non-small cell lung cancer and thyroid cancer. RET Abnormalities can lead to abnormal activation of downstream signaling pathways and promote the proliferation and survival of tumor cells. Platinib inhibits tumor progression by highly selectively inhibiting RET kinase activity, thereby blocking the growth signals of tumor cells. Compared with traditional chemotherapy or broad-spectrum tyrosine kinase inhibitors, platinib is more targeted and has relatively fewer side effects.

Platinib has shown significant efficacy in patients with RETfusion-positive non-small cell lung cancer. Clinical trial results show that Platinib achieved a high objective response rate (ORR) in both untreated and previously treated patient groups, and the response duration was longer. This provides a new treatment option for patients with RET fusion mutations who previously lacked effective treatments. Compared with other broad-spectrum multi-target inhibitors, platinib has shown clear advantages in improving disease control rate and prolonging progression-free survival (PFS).

In the field of thyroid cancer, especially in RETfusion-related papillary thyroid cancer and RET mutation-related medullary thyroid cancer, platinib also shows good clinical value. The drug can not only significantly reduce tumor size, but also relieve tumor-related symptoms and improve patients' quality of life. Platinib is more targeted and tolerable than radioactive iodine therapy or chemotherapy, making it an important treatment option for patients with advanced or relapsed disease.

In general, platinib has shown unique advantages in the treatment of RET fusion-positive non-small cell lung cancer and thyroid cancer by precisely targeting the RET mutation pathway. It overcomes the shortcomings of limited efficacy and severe side effects in previous treatments, and opens up a new direction for personalized precision medicine. With the continuous promotion of clinical application and the accumulation of long-term follow-up data, platinib is expected to further optimize the treatment pattern of RET-related tumors and bring more lasting and safe benefits to patients.

Reference link:https://www.drugs.com